The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Open accessAbstract
OBJECTIVES: To provide updated estimates of Alzheimer disease (AD) dementia prevalence in the United States from 2010 through 2050. METHODS: Probabilities of AD dementia incidence were calculated from a longitudinal, population-based study including substantial numbers of both black and white participants. Incidence probabilities for single year of age, race, and level of education were calculated using weighted logistic regression and AD dementia diagnosis from 2,577 detailed clinical evaluations of 1,913 people obtained from stratified random samples of previously disease-free individuals in a population of 10,800. These were combined with US mortality, education, and new US Census Bureau estimates of current and future population to estimate current and future numbers of people with AD dementia in the United States. RESULTS: We estimated that in 2010, there were 4.7 million individuals aged 65 years or older with AD dementia (95% confidence interval [CI] = 4.0-5.5). Of these, 0.7 million (95% CI = 0.4-0.9) were between 65 and 74 years, 2.3 million were between 75 and 84 years (95% CI = 1.7-2.9), and 1.8 million were 85 years or older (95% CI = 1.4-2.2). The total number of people with AD dementia in 2050 is projected to be 13.8 million, with 7.0 million aged 85 years or older. CONCLUSION: The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the U.S. population ages, the number of people with Alzheimer’s disease and related dementias (ADRD) is rapidly increasing,1,2”
From Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sex is an important factor that contributes to the clinical and biological heterogeneities in Alzheimer’s disease (AD)”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The aging of the baby-boom generation will significantly increase the number of people in the United States with Alzheimer's.70”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“The aging of the population, including the baby‐boom generation, will significantly increase the number of people in the United States with Alzheimer's dementia.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [78]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Of all AD patients in the United States, around two-thirds are women [2].”
From Sex specific molecular networks and key drivers of Alzheimer’s disease (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Almost two-thirds of AD patients in the U.S. are women [2]”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Self-citationPrevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,802
2005 American Community Survey 1-Year Estimates
(2016) · Cited by 1,241
Missed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors
Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P., & Singh, H. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181a6bebc · Cited by 969
Glover, J. W. (2010) · Cited by 917
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Research works printed but not linked: 1
- Bienias JL Kott PS Evans DA. Applying the delete-a-group jacknife varience estimator to analyses of data from a complex longitudinal survey . Proceedings of the Annual Meeting of the American Statistical Association Section on Survey Research Methods. Alexandria: American Statistical Association; 2003:539–544.
Cited by
Sorted by citations
Items 801–900 of 1,012
Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease
Alwatban, M. R., Murman, D. L., & Bashford, G. R. (2019) · Journal of Neuroimaging · doi:10.1111/jon.12606 · Cited by 35
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Zamanian, M. Y., Bazmandegan, G., Sureda, A., Sobarzo‐Sánchez, E., Yousefi‐Manesh, H., & Shirooie, S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200510020744 · Cited by 44
Dementia-related psychosis and the potential role for pimavanserin
Cummings, J. L., Devanand, D. P., & Stahl, S. M. (2020) · CNS Spectrums · doi:10.1017/s1092852920001765 · Cited by 35
Dhana, K., Aggarwal, N. T., Rajan, K. B., Barnes, L. L., Evans, D. A., & Morris, M. C. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab033 · Cited by 36
“One in 10 Americans aged 65 years or more has Alzheimer dementia (AD) (1, 2).”
BackgroundSelf-citationTemperature-Dependent Structural Variability of Prion Protein Amyloid Fibrils
Žiaunys, M., Sakalauskas, A., Mikalauskaitė, K., Sniečkutė, R., & Smirnovas, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105075 · Cited by 36
“Considering that amyloid diseases affect millions of people worldwide and the number is expected to continuously increase [8,9], it is of vital importance to gain a better understanding of the intricacies of amyloid aggregation.”
BackgroundWang, Q., Davis, P. B., Qi, X., Chen, S. G., Gurney, M. E., Perry, G. L., Doraiswamy, P. M., & Xu, R. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00917-1 · Cited by 35
Roberts, A. L., ZAFONTE, R. D., Chibnik, L. B., Baggish, A. L., Taylor, H. A., Baker, J. S., Whittington, A. J., & Weisskopf, M. G. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.3299 · Cited by 36
Dorostgou, Z., Yadegar, N., Dorostgou, Z., Khorvash, F., & Vakili, O. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25094 · Cited by 35
Oudin, A., Forsberg, B., Lind, N., Nordin, S., Åström, D. O., Sundström, A., & Nordin, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-13048-1 · Cited by 35
Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease
Burnham, V. L., & Thornton, J. E. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.05.010 · Cited by 34
Long-term and short-term predictors of worries about getting Alzheimer’s disease
Cutler, S. J., & Ilinca, C. (2015) · European Journal of Ageing · doi:10.1007/s10433-015-0350-3 · Cited by 35
Ehtewish, H., Mesleh, A. G., Ponirakis, G., de la Fuente, A., Parray, A., Bensmail, I., Abdesselem, H., Ramadan, M., Khan, S., Chandran, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098117 · Cited by 37
Wang, Y., Jin, J., Wu, G., Wei, W., Jin, Q., & Wang, X. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2313181 · Cited by 35
“Currently, more than 40 million people worldwide are suffering from AD (Hebert et al. 2013), and the World Health Organization predicts that this number will triple in the next 20 years.”
D’Souza, M. F., Davagnino, J., Hastings, S. N., Sloane, R. J., Kamholz, B. A., & Twersky, J. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13448 · Cited by 34
Knopman, D. S., Roberts, R. O., Pankratz, V. S., Cha, R. H., Rocca, W. A., Mielke, M. M., Boeve, B. F., Tangalos, E. G., Ivnik, R. J., Geda, Y. E., et al. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu103 · Cited by 37
Zhu, F., Panwar, B., Dodge, H. H., Li, H., Hampstead, B. M., Albin, R. L., Paulson, H. L., & Guan, Y. (2016) · Scientific Reports · doi:10.1038/srep34567 · Cited by 34
Building research in diet and cognition: The BRIDGE randomized controlled trial
Tussing-Humphreys, L. M., Lamar, M., Blumenthal, J. A., Babyak, M. A., Fantuzzi, G., Blumstein, L. B., Schiffer, L. A., & Fitzgibbon, M. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.003 · Cited by 34
Phillips, L. J., Birtley, N. M., Petroski, G. F., Siem, C., & Rantz, M. (2018) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12488 · Cited by 34
Detection of amyloid β oligomers toward early diagnosis of Alzheimer's disease
Hwang, S., Chan, H. K., Sorci, M., Deventer, J. A. V., Wittrup, K. D., Belfort, G., & Walt, D. R. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.09.011 · Cited by 36
The Role of Neuroinflammation in Neurodegenerative Disorders
Suescun, J., Chandra, S., & Schiess, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00013-3 · Cited by 34
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 36
Gilson, A. M., Dodds, D., Kaur, A., Potteiger, M., & Ford, J. H. (2019) · JMIR Formative Research · doi:10.2196/14530 · Cited by 34
SERF engages in a fuzzy complex that accelerates primary nucleation of amyloid proteins
Meinen, B. A., Gadkari, V. V., Stull, F. W., Ruotolo, B. T., & Bardwell, J. C. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913316116 · Cited by 34
Silica Nanodepletors: Targeting and Clearing Alzheimer's β‐Amyloid Plaques
Jung, H., Chung, Y. J., Wilton, R., Lee, C. H., Lee, B. I., Lim, J., Lee, H., Choi, J., Kang, H., Lee, B., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910475 · Cited by 34
Krahn, A. I., Wells, C. I., Drewry, D. H., Beitel, L. K., Durcan, T. M., & Axtman, A. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00176 · Cited by 33
Chávez‐Fumagalli, M. Á., Shrivastava, P., Aguilar-Pineda, J. A., Nieto-Montesinos, R., Dávila-Del-Carpio, G., Peralta-Mestas, A., Zeballos, C. C., Valdez-Lazo, G., Fernandez-Macedo, V., Pino‐Figueroa, A. J., et al. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200263 · Cited by 34
“States (US) [1, 4] and its numbers and proportions will increase rapidly in coming years, as the population of Americans at age 65 and older is projected to grow from 56 million in 2020 to 88 million by 2050 [5].”
BackgroundFredriksen‐Goldsen, K. I., Jung, H. H., Kim, H., Petros, R., & Emlet, C. A. (2021) · Journal of Aging and Health · doi:10.1177/08982643211046466 · Cited by 35
Dong, X. Z., Jiang, H. F., Li, S., & Zhang, D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.712237 · Cited by 36
Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson’s diseases
Garfias, S., Domínguez, B. T., Rojas, A. T., Arroyo, M., Rodríguez, U., Boll, M., Sosa, A. L., Sciutto, E., Adalid-Peralta, L. V., López, Y. M., et al. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2018.10.022 · Cited by 33
Increased Long-Term Risk of Dementia in Patients With Carbon Monoxide Poisoning
Wong, C., Lin, Y., Hong, L.-Y., Chen, T.-T., Ma, H., Hsu, Y., Tsai, S., Lin, Y., & Wu, M. (2016) · Medicine · doi:10.1097/md.0000000000002549 · Cited by 34
Distinct sex-specific DNA methylation differences in Alzheimer’s disease
C. Silva, T., Zhang, W., Young, J. I., Gomez, L., Schmidt, M. A., Varma, A., Chen, X. S., Martin, E. R., & Wang, L. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01070-z · Cited by 33
“Almost two thirds of AD patients in the USA are women [9].”
BackgroundGhosal, R., Varma, V. R., Volfson, D., Hillel, I., Urbanek, J. K., Hausdorff, J. M., Watts, A. S., & Zipunnikov, V. (2021) · Biostatistics · doi:10.1093/biostatistics/kxab041 · Cited by 35
Alzheimer's disease: 120 years of research and progress
Ciurea, V., Covache-Busuioc, R.-A., Mohan, A. G., Costin, H. P., & Voicu, V. A. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2022-0111 · Cited by 37
Liu, S., Xu, L., Shen, Y., Wang, L., Lai, X.-X., & Hu, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117031 · Cited by 33
Shastri, D., Raj, V., & Lee, S.-K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102379 · Cited by 34
Liu, W., Lang, M., Youdim, M. B. H., Amit, T., Sun, Y., Zhang, Z., Wang, Y., & Weinreb, O. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.013 · Cited by 33
Team‐Based Interprofessional Competency Training for Dementia Screening and Management
Tan, Z. S., Damron‐Rodriguez, J., Cadogan, M. P., Gans, D., Price, R. M., Merkin, S. S., Jennings, L. A., Schickedanz, H. B., Shimomura, S. K., Osterweil, D., et al. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14540 · Cited by 33
Acidity and Acid-Sensing Ion Channels in the Normal and Alzheimer’s Disease Brain
Gonzales, E. B., & Sumien, N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161131 · Cited by 32
Viaña, J. N. M., Vickers, J. C., Cook, M. J., & Gilbert, F. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.001 · Cited by 33
Daras, L. C., Feng, Z., Wiener, J. M., & Kaganova, Y. (2017) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/0046958017696757 · Cited by 34
Aigbogun, M. S., Stellhorn, R., Krasa, H. B., & Kostic, D. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.001 · Cited by 33
Bansal, A., Kirschner, M., Zu, L., Cai, D., & Zhang, L. (2018) · Brain Research · doi:10.1016/j.brainres.2018.10.001 · Cited by 33
Thiazole‐substituted benzoylpiperazine derivatives as acetylcholinesterase inhibitors
Şahin, Z., Ertaş, M., Bender, C., Bülbül, E. F., Berk, B., Biltekin, S. N., Yurttaş, L., & Demirayak, Ş. (2018) · Drug Development Research · doi:10.1002/ddr.21481 · Cited by 33
Glioma and Alzheimer’s Disease
Lehrer, S. P. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180084 · Cited by 34
Peterson, R. L., Fain, M. J., Butler, E. A., Ehiri, J. E., & Carvajal, S. C. (2019) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2019.1598539 · Cited by 33
Ben-Nejma, I. R. H., Keliris, A., Daans, J., Ponsaerts, P., Verhoye, M., der Linden, A. V., & Keliris, G. A. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0810-7 · Cited by 35
Kim, D., Jeong, S., & Lee, J. (2020) · Journal of Periodontal & Implant Science · doi:10.5051/jpis.2000600030 · Cited by 33
“The brains of AD patients present with extraneuronal plaques formed by the buildup of the amyloid β-peptide (Aβ) protein, as well as intraneuronal tau tangles, which are abnormal tangled bundles of the phosphorylated tau (P-tau) protein [4,5].”
BackgroundRacial/Ethnic Differences in Health‐Related Quality of Life in Persons With and Without Dementia
Hayes‐Larson, E., Mobley, T. M., Gilmore‐Bykovskyi, A. L., Shaw, C. L., Karlamangla, A. S., Manly, J. J., & Mayeda, E. R. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16908 · Cited by 33
“Given the lack of effective pharmacologic strategies to prevent, slow, or reverse progression of dementia, maximizing quality of life (QOL) is a major priority for the more than 5 million Americans living with dementia and their caregivers.(1,2) Quality of life is a broad construct, often including four major dimensio…”
BackgroundJankovská, N., Olejár, T., & Matěj, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010007 · Cited by 35
Brain Health: Attitudes towards Technology Adoption in Older Adults
Abdelrahman, N. G., Haque, R., Polverento, M. E., Wendling, A. L., Goetz, C. M., & Arnetz, B. B. (2020) · Healthcare · doi:10.3390/healthcare9010023 · Cited by 35
“Age-related decline in brain health represents a great personal and financial burden to individuals, families, healthcare, and social services [3,4].”
BackgroundTournissac, M., Vu, T.-M., Vrabic, N., Hozer, C., Tremblay, C., Mélançon, K., Planel, E., Pifferi, F., & Calon, F. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00842-3 · Cited by 34
Dumitrascu, O. M., Rosenberry, R., Sherman, D. S., Khansari, M. M., Sheyn, J., Torbati, T., Sherzai, A. Z., Sherzai, D., Johnson, K., Czeszynski, A., et al. (2021) · Cells · doi:10.3390/cells10112926 · Cited by 31
“1 million, which is almost a 22% increase from 2020 [1,2].”
BackgroundWakhloo, D., Mahajani, S. U., Oberhauser, J., & Madira, A. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336138 · Cited by 38
“Although aging is considered to be one of the most important risk factors for AD (Hebert et al., 2013), multiple genetic mutations have been implicated in the disease, including PSEN1 , PSEN2 and APP (Lin et al., 2020).”
Desai, R. J., Mahesri, M., Lee, S. B., Varma, V. R., Loeffler, T., Schilcher, I., Gerhard, T., Segal, J. B., Ritchey, M. E., Horton, D. B., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac247 · Cited by 33
Conceptualizing and Operationalizing Collaboration Among Multiple Caregivers of Older Adults
Ellis, K. R., Koumoutzis, A., Lewis, J., Lin, Z., Zhou, Y., Chopik, W. J., & Gonzalez, R. (2022) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbac139 · Cited by 33
“Most individuals with dementia reside in communities with the support of friend or family care-givers (Hebert et al., 2013).”
Brenowitz, W. D., Kukull, W. A., Beresford, S. A. A., Monsell, S. E., & Williams, E. C. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000020 · Cited by 35
Involvement of the Bradykinin B1 Receptor in Microglial Activation: In Vitro and In Vivo Studies
Asraf, K., Torika, N., Danon, A., & Fleisher‐Berkovich, S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00082 · Cited by 35
Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?
Grizzanti, J., Corrigan, R. R., Servizi, S., & Casadesús, G. (2019) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2019/1.1212 · Cited by 31
Sex Difference in Spinal Muscular Atrophy Patients – are Males More Vulnerable?
Sun, J., Harrington, M. A., Porter, B., & on behalf of the TREAT-NMD Global Registry Network for SMA (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-230011 · Cited by 31
Hatami, M., Yaghmaee, F., & Ebrahimpour, R. (2024) · Neurocomputing · doi:10.1016/j.neucom.2024.128119 · Cited by 34
Current and Emerging Therapies for Alzheimer’s Disease
Nygaard, H. B. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.009 · Cited by 32
H63D mutation in hemochromatosis alters cholesterol metabolism and induces memory impairment
Ali-Rahmani, F. G., Grigson, P. S., Lee, S. Y., Neely, E. B., Connor, J. R., & Schengrund, C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.014 · Cited by 32
Brain Arterial Diameters and Cognitive Performance: The Northern Manhattan Study
Gutierrez, J., Kulick, E. R., Moon, Y. P., Dong, C., Cheung, K., Bagci, A. M., Stern, Y., Alperin, N. J., Rundek, T., Sacco, R. L., et al. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617717001175 · Cited by 34
Lee, J., Ahn, S.-Y., Lee, H. A., Won, K. S., Chang, H. W., Oh, J. S., & Kim, H. W. (2018) · Food & Nutrition Research · doi:10.29219/fnr.v62.1415 · Cited by 32
Personalized dynamic transport of magnetic nanorobots inside the brain vasculature
Chen, J., & Wang, Y. (2020) · Nanotechnology · doi:10.1088/1361-6528/abb392 · Cited by 33
Evaluation of chronic lead effects in the blood brain barrier system by DCE-CT
Gu, H., Territo, P. R., Persohn, S. A., Bedwell, A. A., Eldridge, K., Speedy, R., Chen, Z., Zheng, W., & Du, Y. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126648 · Cited by 35
Stebbins, R. C., Noppert, G. A., Yang, Y. C., Dowd, J. B., Simanek, A. M., & Aiello, A. E. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa238 · Cited by 31
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
Vogrinc, D., Goričar, K., & Dolžan, V. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.646901 · Cited by 32
“8% of all people globally will be affected by the 2050 (Brookmeyer et al., 2007; Hebert et al., 2013).”
BackgroundSex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults
Palta, P., Rippon, B., Tahmi, M., Pardo, M., Johnson, A. S., Tomljanovic, Z., He, H., Laing, K. K., Razlighi, Q. R., Teresi, J. A., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.03.007 · Cited by 33
Ornstein, K. A., Ankuda, C. K., Leff, B. A., Rajagopalan, S., Siu, A. L., Harrison, K. L., Oh, A., Reckrey, J. M., & Ritchie, C. S. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17621 · Cited by 32
Migraine and the risk of dementia: a meta-analysis and systematic review
Jiang, W., Liang, G.-H., Li, J., Yu, P., & Dong, M. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-02065-w · Cited by 32
Zhu, N., Wei, M., Yuan, L., He, X., Chen, C., Ji, A., & Zhang, G. (2022) · Aging · doi:10.18632/aging.204029 · Cited by 34
Mork, D., Braun, D., & Zanobetti, A. (2022) · Environment International · doi:10.1016/j.envint.2022.107694 · Cited by 34
Brooks, L. R. K., & Mias, G. I. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00392 · Cited by 32
β-Amyloid Biomarker Detection for Alzheimer’s Disease
Li, C.-Z., Grajales, S. A., Shuang, S., Dong, C., & Nair, M. G. (2017) · Journal of Analysis and Testing · doi:10.1007/s41664-017-0014-8 · Cited by 31
Goldstein, F. C., Hajjar, I. M., Dunn, C. B., Levey, A. I., & Wharton, W. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw181 · Cited by 32
Roy, J., & Mallick, B. (2017) · Genomics · doi:10.1016/j.ygeno.2017.02.006 · Cited by 35
Leung, M., Wang, C., & Wei, X. (2019) · Building and Environment · doi:10.1016/j.buildenv.2019.106532 · Cited by 31
Hasan, A. H., Amran, S. I., Hussain, F. H. S., Jaff, B. A., & Jamalis, J. (2019) · ChemistrySelect · doi:10.1002/slct.201903607 · Cited by 31
Centenarians as Models of Resistance and Resilience to Alzheimer’s Disease and Related Dementias
Andersen, S. L. (2020) · Advances in Geriatric Medicine and Research · doi:10.20900/agmr20200018 · Cited by 35
“Older age is the biggest risk factor for AD [11] yet many centenarians, individuals who have surpassed the average life expectancy of their peers by more than two decades, avoid pathologically defined AD and/or clinical dementia [12,13].”
BackgroundPrecision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics
Gavriilaki, M., Kimiskidis, V. Κ., & Gavriilaki, E. (2020) · Pharmaceuticals · doi:10.3390/ph13110341 · Cited by 32
Posner, A. B., Tranah, G. J., BLACKWELL, T. L., Yaffe, K. S., Ancoli‐Israel, S., Redline, S. S., Leng, Y., Zeitzer, J. M., Chen, D. M., Webber, K., et al. (2021) · SLEEP · doi:10.1093/sleep/zsab119 · Cited by 32
On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
Kriška, J., Heřmanová, Z., Knotek, T., Turečková, J., & Anděrová, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189689 · Cited by 33
Du, X. L., Song, L., Schulz, P. E., Xu, H., & Chan, W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215657 · Cited by 30
Sleep Signal Analysis for Early Detection of Alzheimer's Disease and Related Dementia (ADRD)
Khosroazad, S., Abedi, A., & Hayes, M. J. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3235391 · Cited by 31
“8 million Americans of all ages have Alzheimer’s disease [1], [2].”
BackgroundVisceral adiposity predicts subclinical white matter hyperintensities in middle-aged adults
Pasha, E. P., Birdsill, A. C., Parker, P., Elmenshawy, A. R., Tanaka, H., & Haley, A. P. (2016) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2016.04.003 · Cited by 33
Nair, B., Browne, W., Marley, J. E., & Heim, C. (2013) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s35762 · Cited by 30
Zhu, J., Chen, X., Song, Y., Zhang, Y., Zhou, L., & Wan, L. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.014 · Cited by 31
Bailes, C. O., Kelley, C. M., & Parker, N. M. (2016) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12355 · Cited by 30
Pain and Emergency Department Use in the Last Month of Life Among Older Adults With Dementia
Hunt, L. J., Ritchie, C. S., Cataldo, J. K., Patel, K., Stephens, C. E., & Smith, A. K. (2018) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2018.09.005 · Cited by 30
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease
Zakaria, J. A. D., & Vassar, R. J. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809717 · Cited by 30
Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease
Fasiolo, L. T., Manniello, M. D., Bortolotti, F., Buttini, F., Rossi, A., Sonvico, F., Colombo, P., Valsami, G. N., Colombo, G., & Russo, P. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1574300 · Cited by 30
Angel, A., Volkman, R., Royal, T. G., & Offen, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031144 · Cited by 30
Mechanisms of Electroacupuncture on Alzheimer’s Disease: A Review of Animal Studies
Song, Y., Xu, W., Zhang, X.-C., & Ni, G.-X. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3092-9 · Cited by 29
Zhang, S., Li, L., Hu, J., Ma, P., & Zhu, H. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1817102 · Cited by 30
Ricci, M., Cimini, A., Chiaravalloti, A., Filippi, L., & Schillaci, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207481 · Cited by 33
“Alzheimer’s disease is the most common neurodegenerative dementia from middle age to the elderly, with a prevalence of 5–6% of all individuals over the age of 65, reaching 30% in those over the age of 85 [3].”
BackgroundPark, J.-H., Park, I., Youm, E. M., Lee, S., Park, J.-H., Lee, J., Lee, D. Y., Byun, M. S., Lee, J. H., Yi, D., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01412-9 · Cited by 30
“In the United States, the prevalence of AD in people aged 65 years and older is forecast to increase from 4.7% in 2010 to 13.8% in 2050 2,3 .”
InfluentialMicroglia and its Genetics in Alzheimer's Disease
Liang, X., Wu, H., Colt, M., Guo, X., Pluimer, B. R., Zeng, J., Dong, S., & Zhao, Z. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211105140732 · Cited by 32
Carota, A. G., Campanella, B., Carratore, R. D., Bongioanni, P., Giannelli, R., & Legnaioli, S. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04087-3 · Cited by 30
Metadata
- Authors
- Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A.
- Affiliations
- Rush University (US)
- Venue
- Neurology
- Published
- 2013-05-07
- Volume
- 80
- Issue
- 19
- Pages
- 1778-1783
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC3719424
- OpenAlex
- W2071068165
- Cited by
- 2,642
- References
- 19
- Citations by year
- 2026: 81 · 2025: 119 · 2024: 192 · 2023: 167 · 2022: 242 · 2021: 312 · 2020: 317 · 2019: 232 · 2018: 210 · 2017: 212 · 2016: 217 · 2015: 160 · 2014: 129 · 2013: 47
- FWCI
- 131.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institutes of Health (AG011101)
- National Institute on Aging (RC2AG036650, U01AG012505, R01AG030146, AG011101, R01AG011101, P30AG010161, R01AG021972, R01AG009966)
- National Heart, Lung, and Blood Institute (R01HL084209)
- National Institute of Nursing Research (R01NR009543, R01NR010211)
- National Institute of Environmental Health Sciences (R21ES020404, R01ES010902, R21ES019712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Social Sciences › Demography › Insurance, Mortality, Demography, Risk Management
- Keywords
- Alzheimer's disease, dementia prevalence, population projections, older adults, age-specific prevalence, racial differences, educational attainment, population aging, United States
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Forecasting, Humans, Longitudinal Studies, Male, Population Surveillance, United States, Incidence, Censuses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
